• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Alumis Inc.

    7/3/24 4:47:32 PM ET
    $ALMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALMS alert in real time by email
    SC 13D 1 p24-2316sc13d.htm ALUMIS INC.

     

    SECURITIES AND EXCHANGE COMMISSION  
    Washington, D.C. 20549  
       
    SCHEDULE 13D
     
    Under the Securities Exchange Act of 1934
    (Amendment No. __)*
     

    Alumis Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    022307102

    (CUSIP Number)
     
    Gregory A. Brown
    AyurMaya Capital Management Company. LP
    Bay Colony Corporate Center
    1000 Winter Street, Suite 4500
    Waltham, MA 02451
     
    Eleazer Klein, Esq.
    Adriana Schwartz, Esq.
    Schulte Roth & Zabel LLP
    919 Third Avenue
    New York, NY 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    July 1, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ¨

    (Page 1 of 9 Pages)

    ______________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 022307102SCHEDULE 13DPage 2 of 9 Pages

     

    1

    NAME OF REPORTING PERSON

    AyurMaya Capital Management Company, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    0

    8

    SHARED VOTING POWER

    10,645,966 shares of Common Stock

    9

    SOLE DISPOSITIVE POWER

    0

    10

    SHARED DISPOSITIVE POWER

    10,645,966 shares of Common Stock

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    10,645,966 shares of Common Stock

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    22.57%

    14

    TYPE OF REPORTING PERSON

    PN, IA

             

     

     

    CUSIP No. 022307102SCHEDULE 13DPage 3 of 9 Pages

     

    1

    NAME OF REPORTING PERSON

    David E. Goel

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    0

    8

    SHARED VOTING POWER

    10,645,966 shares of Common Stock

    9

    SOLE DISPOSITIVE POWER

    0

    10

    SHARED DISPOSITIVE POWER

    10,645,966 shares of Common Stock

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    10,645,966 shares of Common Stock

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    22.57%

    14

    TYPE OF REPORTING PERSON

    IN, HC

             

     

     

    CUSIP No. 022307102SCHEDULE 13DPage 4 of 9 Pages

     

    Item 1. SECURITY AND ISSUER:
       
      This statement on Schedule 13D (the "Schedule 13D") relates to the Common Stock, par value $0.0001 per share (the "Common Stock"), of Alumis Inc., a Delaware corporation (the "Issuer").  The Issuer's principal executive offices are located at 280 East Grand Avenue, South San Francisco, CA 94080.
       
    Item 2. IDENTITY AND BACKGROUND:
       
    (a)-(c), (f) This Schedule 13D is being jointly filed by (i) AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, and the investment advisor to AyurMaya Capital Management Fund, LP (the “AyurMaya Fund”), with respect to the shares of Common Stock held by the AyurMaya Fund; and (ii) Mr. David E. Goel ("Mr. Goel"), who serves as the Managing Member of  AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager, with respect to the shares of  Common Stock held by the AyurMaya Fund.
       
      The Investment Manager and Mr. Goel are sometimes also referred to herein individually as a "Reporting Person" and collectively as the "Reporting Persons".
       
      The address of the business office of each of the Reporting Persons is c/o AyurMaya Capital Management Company, LP, Bay Colony Corporate Center, 1000 Winter Street, Suite 4500, Waltham, MA 02451.
       
      The principal business of each of the Reporting Persons is the management of investment funds and activities related thereto.
       
      The filing of this statement should not be construed in and of itself as an admission by the Reporting Persons as to beneficial ownership of the securities reported herein.
       
    (d)-(e) During the last five (5) years, none of the Reporting Persons has: (1) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (2) been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

     

     

    CUSIP No. 022307102SCHEDULE 13DPage 5 of 9 Pages

     

    Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION:
       
      The AyurMaya Fund acquired (i) 4,278,074 shares of Common Stock upon the automatic conversion of 20,000,000 shares of the Issuer's Series B Redeemable Convertible Preferred Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"); (ii) 1,141,494 shares of Common Stock upon the automatic conversion of 5,336,489 shares of Series B-2 Redeemable Convertible Preferred Stock immediately prior to the closing of the Issuer’s IPO; (iii) 2,726,398  shares of Common Stock upon the automatic conversion of 12,745,916 shares of Series C Redeemable Convertible Preferred Stock immediately prior to the closing of the Issuer’s IPO (the shares of Common Stock referred to in clauses (i) through (iii) are collectively referred to herein as the "Conversion Shares")  and (iv) 2,500,000 Private Placement Shares (as defined in Item 6) at a price of $16 per Private Placement Share. Funds for the purchase of the Private Placement Shares were derived from general working capital of the AyurMaya Fund. A total of $40,000,000 was paid to acquire the Private Placement Shares.
       
    Item 4. PURPOSE OF TRANSACTION:
       
      Immediately prior to the closing of the IPO, the AyurMaya Fund acquired the Conversion Shares and the Private Placement Shares (as defined in Item 6).
       
      Alan Colowick, a Senior Managing Director of Matrix Capital Management Company LP, an affiliate of the Investment Manager, serves on the board of directors of the Issuer.
       
      The Reporting Persons have had and anticipate having further discussions with officers and directors of the Issuer in connection with the Reporting Persons' investment in the Issuer. The topics of these conversations have covered and will cover a range of issues, including those relating to the business of the Issuer, management, board composition, investor communications, operations, capital allocation, dividend policy, financial condition, mergers and acquisitions strategy and strategic plans, overall business strategy, executive compensation, corporate governance and environmental and social matters related to the Issuer's business and stakeholders.  The Reporting Persons may also have similar conversations with other stockholders or other interested parties, such as industry analysts, existing or potential strategic partners or competitors, investment professionals and other investors and may exchange information with any such persons or the Issuer pursuant to appropriate confidentiality or similar agreements (which may contain customary standstill provisions).  The Reporting Persons may at any time reconsider and change their intentions relating to the foregoing.  The Reporting Persons may also take one or more of the actions described in subsections (a) through (j) of Item 4 of Schedule 13D and may discuss or propose such actions with the Issuer's management and the board of directors of the Issuer, other stockholders of the Issuer, and other interested parties, such as those set out above.  The Reporting Persons intend to review their investments in the Issuer on a continuing basis.  Depending on various factors, including, without limitation, the Issuer's financial position and strategic direction, the outcome of the discussions and actions referenced above, actions taken by the Issuer's board of directors, price levels of the Common Stock, liquidity requirements and other investment opportunities available to the Reporting Persons, conditions in the securities market and general economic and industry conditions, the Reporting Persons may in the future take actions with respect to their investment position in the Issuer as they deem appropriate, including, without limitation, purchasing additional shares of Common Stock or other instruments that are based upon or relate to the value of the Common Stock or the Issuer in the open market or otherwise, selling some or all of the securities reported herein, and/or engaging in hedging or similar transactions with respect to the shares of Common Stock.
       

     

     

    CUSIP No. 022307102SCHEDULE 13DPage 6 of 9 Pages

     

       
    Item 5. INTEREST IN SECURITIES OF THE ISSUER:
       
    (a) See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned by each Reporting Person.  The percentages used in this Schedule 13D as of the date hereof are calculated based upon 47,159,821 shares of Common Stock reported to be outstanding in the Issuer's Free Writing Prospectus filed with the Securities and Exchange Commission on June 28, 2024, after giving effect to the completion of the offering and the concurrent private placement, as described therein.
       
    (b) See rows (7) through (10) of the cover pages to this Schedule 13D for the number of shares of Common Stock as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
       
    (c) Other than as disclosed in Item 3, no transactions in the shares  of  Common Stock have been effected by the Reporting Persons during the past sixty (60) days.
       
    (d) No person other than the Reporting Persons and the AyurMaya Fund is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the shares of Common Stock held by the AyurMaya Fund.
       
    (e) Not applicable.

     

     

     

    CUSIP No. 022307102SCHEDULE 13DPage 7 of 9 Pages

     

    Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER:
       
     

    On June 27, 2024, the AyurMaya Fund entered into a Common Stock Purchase Agreement (the “Common Stock Purchase Agreement”) for the purchase from the Issuer in a private placement of an aggregate of 2,500,000 shares of Common Stock (the “Private Placement Shares”) at a purchase price of $16.00 per share (the “Private Placement”). The closing of the Private Placement is contingent on the closing of the IPO. However, the closing of the IPO is not contingent on the closing of the Private Placement, which is expected to occur on or before 21 days after the closing of the IPO. The foregoing summary of the Common Stock Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Common Stock Purchase Agreement, which has been filed as Exhibit 99.1 hereto and incorporated by reference herein.

    On March 4, 2024, the AyurMaya Fund entered into an Amended and Restated Investors’ Rights Agreement with the Issuer (the “Investors’ Rights Agreement”), which grants customary registration rights to the AyurMaya Fund with respect to the securities held by it, including the Private Placement Shares. The foregoing summary of the Investors’ Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Investors’ Rights Agreement, which has been filed as Exhibit 99.2 hereto and incorporated by reference herein.

     

    In connection with the IPO, the AyurMaya Fund entered into a lock-up agreement with the underwriters of the IPO that, until 180 days from the date of the Issuer’s final prospectus relating to the IPO without the prior written consent of the representatives of the underwriters that participated in the IPO, and subject to certain exceptions, restricts its ability to offer, sell or otherwise transfer or dispose its shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock (including shares of the Issuer’s non-voting common stock), or enter into any hedging, swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the securities, whether any such swap or transaction is to be settled by delivery of our common stock or other securities, in cash or otherwise (the “IPO Lock-Up Agreement”).

     

     

    The foregoing summary of the IPO Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the IPO Lock-Up Agreement, the form of which has been filed as Exhibit 99.3 hereto and incorporated by reference herein.

     

      Except as otherwise described in this Schedule 13D and the Joint Filing Agreement attached as Exhibit 99.4 hereto, there are no contracts, arrangements, understandings or similar relationships with respect to the securities of the Issuer between any of the Reporting Persons and any other person or entity.

     

     

    CUSIP No. 022307102SCHEDULE 13DPage 8 of 9 Pages

     

    Item 7. MATERIAL TO BE FILED AS EXHIBITS:
       
    Exhibit 99.1: Common Stock Purchase Agreement, dated as of June 27, 2024 (incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 3, 2024).
       
    Exhibit 99.2: Amended and Restated Investors’ Rights Agreement, dated as of March 4, 2024 (incorporated by reference to Exhibit 4.2 of the Issuer’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on June 7, 2024).
       
    Exhibit 99.3: Form of Lock-Up Agreement (incorporated herein by reference to Exhibit A attached to the Underwriting Agreement, by and among the applicable locked-up party and Morgan Stanley & Co. LLC, Leerink Partners LLC, Cantor Fitzgerald & Co. and Guggenheim Securities, LLC, as representatives of the several underwriters named therein, attached as Exhibit A to Exhibit 1.1 to Amendment No. 2 to the Issuer’s Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on June 24, 2024).
       
    Exhibit 99.4: Joint Filing Agreement, dated July 3, 2024.

     

     

     

    CUSIP No. 022307102SCHEDULE 13DPage 9 of 9 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: July 3, 2024

     

     

    AYURMAYA CAPITAL MANAGEMENT COMPANY, LP

    By: AyurMaya Capital Management Company GP, LLC, its General Partner

       
         
         
    By: /s/ David E. Goel    
    Name: David E. Goel    
    Title: Managing Member    
         
         
    /s/ David E. Goel    
    DAVID E. GOEL    

     

     

     

    Get the next $ALMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALMS

    DatePrice TargetRatingAnalyst
    1/30/2025$32.00Outperform
    Oppenheimer
    10/31/2024$25.00Outperform
    Robert W. Baird
    10/17/2024$30.00Buy
    H.C. Wainwright
    7/23/2024Overweight
    Cantor Fitzgerald
    7/23/2024$29.00Outperform
    Leerink Partners
    7/23/2024$32.00Buy
    Guggenheim
    7/23/2024$36.00Overweight
    Morgan Stanley
    More analyst ratings

    $ALMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Alumis with a new price target

      Oppenheimer initiated coverage of Alumis with a rating of Outperform and set a new price target of $32.00

      1/30/25 7:47:22 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Alumis with a new price target

      Robert W. Baird initiated coverage of Alumis with a rating of Outperform and set a new price target of $25.00

      10/31/24 6:14:08 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Alumis with a new price target

      H.C. Wainwright initiated coverage of Alumis with a rating of Buy and set a new price target of $30.00

      10/17/24 7:14:37 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Akkaraju Srinivas was granted 1,214,582 shares (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/23/25 8:47:53 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ayurmaya Capital Management Company, Lp was granted 4,493,741 shares (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/23/25 4:20:51 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Machado Patrick was granted 7,064 shares (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/23/25 4:05:20 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alumis Completes Merger with ACELYRIN

      SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that it has completed its merger with ACELYRIN, Inc. Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned. ACELYRIN common stock has ceased trading and will no longer be listed on the NASDAQ Global Select Market. "We are excited to complete our merger and move forward with a significantly strengthened balance sheet to support Alumis' differentiated late-stage portfolio and develop transformative th

      5/21/25 9:10:51 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

      SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the quarter ended March 31, 2025, and highlighted recent achievements and upcoming milestones. "We're seeing strong momentum across our development programs, with our team continuing to execute effectively following a productive first quarter of 2025," said Martin Babler, President and Chief Executive Officer of Alumis. "This includes advancement of the ongoing

      5/14/25 4:05:00 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alumis Stockholders Approve Merger with ACELYRIN

      SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC. (NASDAQ:SLRN) at its Special Meeting of Stockholders. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, "We thank our stockholders for their support for the merger and with this milestone now complete, we are moving expeditious

      5/13/25 1:00:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tananbaum James B. bought $202,300 worth of shares (45,000 units at $4.50) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/6/25 9:48:59 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Foresite Labs, Llc bought $202,300 worth of shares (45,000 units at $4.50) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/6/25 9:48:12 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Foresite Capital Management Vi Llc bought $202,300 worth of shares (45,000 units at $4.50) (SEC Form 4)

      4 - ALUMIS INC. (0001847367) (Issuer)

      5/6/25 9:47:18 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALMS
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Alumis Inc.

      SCHEDULE 13D/A - ALUMIS INC. (0001847367) (Subject)

      5/23/25 8:49:18 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Alumis Inc.

      SCHEDULE 13D/A - ALUMIS INC. (0001847367) (Subject)

      5/23/25 4:16:27 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alumis Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - ALUMIS INC. (0001847367) (Filer)

      5/21/25 9:15:55 AM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Alumis Inc.

      SC 13D - ALUMIS INC. (0001847367) (Subject)

      8/27/24 4:20:38 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Alumis Inc.

      SC 13G - ALUMIS INC. (0001847367) (Subject)

      7/11/24 4:30:21 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Alumis Inc.

      SC 13D - ALUMIS INC. (0001847367) (Subject)

      7/5/24 9:30:17 PM ET
      $ALMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALMS
    Financials

    Live finance-specific insights

    See more
    • Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

      Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN's lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis Combined company wi

      2/6/25 4:15:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care